June 14, 2013 April Flowers for redOrbit.com Your Universe Online Many students are not diagnosed with dyslexia and other learning disabilities until high school, making treatments less effective. A new study of the genetic origins of these conditions by the Yale School of Medicine could allow for earlier diagnoses and more successful interventions. The research team, led by Jeffrey R. Gruen, MD, professor of pediatrics, genetics and investigative medicine at Yale, analyzed data from more than 10,000 children born in 1991-1992. The children were part of the Avon Longitudinal Study of Parents and Children (ALSPAC) conducted by investigators at the University of Bristol in the UK. The ALSPAC data was used to unravel the genetic components of reading and verbal language. During this process, the team identified genetic variants that can predispose children to dyslexia and language impairment. Understanding this predisposition increases the likelihood of earlier diagnosis and more effective treatments. The development of reading and verbal language skills is difficult with dyslexia and language impairment, which are both common learning disabilities. Both of these disabilities are known to have significant genetic components, but until now determining the root cause had been difficult. Prior research by Gruen and his team … Continue reading →

Washington, June 14 (ANI): Researchers at Yale School of Medicine have discovered genetic variants that can predispose children to dyslexia and language impairment, increasing the likelihood of earlier diagnosis and more effective interventions. Many students now are not diagnosed until high school, at which point treatments are less effective. Senior author Jeffrey R. Gruen, M.D., professor of pediatrics, genetics, and investigative medicine at Yale, and colleagues analyzed data from more than 10,000 children born in 1991-1992 who were part of the Avon Longitudinal Study of Parents and Children (ALSPAC) conducted by investigators at the University of Bristol in the United Kingdom. Dyslexia and language impairment are common learning disabilities that make reading and verbal language skills difficult. Both disorders have a substantial genetic component, but despite years of study, determining the root cause had been difficult. In previous studies, Gruen and his team found that dopamine-related genes ANKK1 and DRD2 are involved in language processing. In further non-genetic studies, they found that prenatal exposure to nicotine has a strong negative affect on both reading and language processing. They had also previously found that a gene called DCDC2 was linked to dyslexia. In this new study, Gruen and colleagues looked deeper … Continue reading →

OMICS Group Incorporation Acquires Journal of Molecular and Genetic Medicine from LibPubMedia OMICS Group Incorporation announces acquisition of Journal of Molecular and Genetic Medicine (JMGM) from the Library Publishing Media. The deal was signed between Dr. Srinu Babu Gedela, CEO, OMICS Group Inc., and Dr. Muhammad Sohail, CEO, Library Publishing Media. Both organizations are working together to strengthen bonds for long-term future relationship. Journal of Molecular and Genetic Medicine (JMGM) offers its scholarly publishing to PubMed and PubMed Central. The journal stands as one of its own kind by publishing high quality articles and exploring the vast discipline of Genetics and Molecular Biology. Started in 2005, it fosters communication between academic research and interdisciplinary commerce of medicine. Burgeoning the Open Access publishing, JMGM enumerates OMICSs vision of dissemination of scientific and healthcare knowledge. Journal of Molecular and Genetic Medicine (JMGM) will particularly focus on biomedical issues of the developing world, centralizing research on malaria, HIV/AIDS, viral hepatitis and microbial diseases. OMICS Group like its other publishings will continue using peculiar Peer-review methodologies and using Editorial Manager System for the same. JMGM is available online and freely accessible over the internet under the running Open Access Policy of OMICS Group. Dr. … Continue reading →

Mayo Clinic First in U.S. Testing Stem Cell Use in Pediatric Congenital Heart Disease Trial Mayo Clinic is announcing the first stem cell clinical trial for pediatric congenital heart disease in the United States. The trial aims to determine how ste... By: Mayo Clinic … Continue reading →

The Alliance for the Advancement of Adult Stem Cell Therapy and Research Billy Orr is a quadriplegic who spent the last quarter century in a wheelchair. You are watching Billy Orr stand and walk for the first time after having adu... By: TheStemCellAlliance … Continue reading →

TAMPA, Fla., June 14, 2013 /PRNewswire/ --Stem cells have long been touted as the next big thing. Well just maybe, it is here. According to Dr. Dennis Lox, some patients with a disorder of the bone called avascular necrosis (AVN), have turned to stem cell therapy for aid. Avascular necrosis (AVN) also referred to as osteonecrosis or ischemic necrosis, is a condition in which the blood supply to the bone becomes disrupted, leading that region of bone to die. This is referred to as necrosis. The region may be very painful, and the region of necrosis may collapse resulting in severe arthritis. This has led to numerous joint replacement surgeries. It is estimated that 20,000 new cases a year of AVN, are diagnosed in the United States. AVN commonly occurs in the hip, shoulder, knee, ankle, and can even be present in multiple joints at the same time. http://www.drlox.com Dr. Dennis Lox, http://www.drlox.com a Regenerative and Sports Medicine physician in the Tampa Bay, Florida area, comments that regenerative therapies such as Platelet Rich Plasma (PRP) and Stem Cell Therapy, are being used to treat avascular necrosis. Dr. Lox reports that what previously was a career ending injury for athletes like … Continue reading →

MagForce AG / Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of MagForce AG . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Berlin, Germany, June 14, 2013 - The Supervisory Board of Magforce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of oncology, has appointed Dr. Ben J. Lipps, former CEO and Chairman of Fresenius Medical Care, as Chairman of the Management Board and Chief Executive Officer of the company starting September 2013. While serving as Chairman and CEO of Magforce, Ben Lipps will continue his consultantship with Fresenius Medical Care. The current management board members of Magforce Prof. Dr. Hoda Tawfik (Chief Developement & Medical Officer) and Christian von Volkmann (Chief Financial Officer) remain in their respective position. Dr. Ben J. Lipps became Chairman and Chief Executive Officer of the Management Board of Fresenius Medical Care in May 1999. In December 2012, he stepped down as Chairman of the Management Board and CEO. Dr. Lipps led the research team that developed the first commercial hollow fiber artificial kidney at the end of the 1960's. Today over two … Continue reading →

Berlin, Germany, June 14, 2013 - The Supervisory Board of Magforce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of oncology, has appointed Dr. Ben J. Lipps, former CEO and Chairman of Fresenius Medical Care, as Chairman of the Management Board and Chief Executive Officer of the company starting September 2013. While serving as Chairman and CEO of Magforce, Ben Lipps will continue his consultantship with Fresenius Medical Care. The current management board members of Magforce Prof. Dr. Hoda Tawfik (Chief Developement & Medical Officer) and Christian von Volkmann (Chief Financial Officer) remain in their respective position. Dr. Ben J. Lipps became Chairman and Chief Executive Officer of the Management Board of Fresenius Medical Care in May 1999. In December 2012, he stepped down as Chairman of the Management Board and CEO. Dr. Lipps led the research team that developed the first commercial hollow fiber artificial kidney at the end of the 1960`s. Today over two million dialysis patients rely on hollow fiber dialyzers for life sustaining treatments. Norbert Neef, Chairman of the Supervisory Board of MagForce, comments: "MagForce is very proud to have attracted a former DAX 30 CEO as addition to MagForce`s management team. … Continue reading →